Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Fund Letter | Amy ZhangAlger Small Cap Focus Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Alger Small Cap Focus Fund 2025 Q4 (NTRA) Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health, oncology led by Signatera, and transplant monitoring. These tests are... | BULL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Patrick Kelly, Dan Chung, Ankur CrawfordAlger Spectra Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Alger Spectra Fund 2025 Q4 (NTRA) Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health, oncology led by Signatera, and transplant monitoring. These tests are... | BULL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | H. George Dai, Joshua D. BennettAlger Weatherbie Specialized Growth Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Alger Weatherbie Specialized Growth Fund 2025 Q4 (NTRA) Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health (including non-invasive prenatal testing for chromosomal conditions such as trisomy 13, 18, and 21), oncology (led by Signatera, which measures circulating tumor DNA to assess treatment response and detect molecular residual disease and cancer recurrence), and transplant (tests used to monitor organ rejection). These tests are... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Andrew Choi & Shivani VohraParnassus Growth Equity Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Parnassus Growth Equity Fund 2025 Q4 (NTRA) Natera continued to outperform during the quarter as adoption of its flagship diagnostic product accelerated. Positive clinical data... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Eric Mintz, Christopher Sassouni, David CavanaughCarillon Eagle Mid Cap Growth Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Carillon Eagle Mid Cap Growth Fund 2025 Q4 (NTRA) Natera is a diagnostics company that provides preconception and prenatal genetic testing services, with its flagship Signatera oncology test driving growth. In the latest... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.